- Path:
-
The role of auto-HSCT in extranodal natural killer/T cell lymphoma
Files
Periodical
- Title:
- Open medicine
- Publication:
-
Berlin: de Gruyter
- Note:
- Open Access
- Namensnennung 4.0 International
- Scope:
- Online-Ressource
- ISSN:
- 2391-5463
- ZDB-ID:
-
2829380-0
- VÖBB-Katalog:
- 35318930
- Keywords:
- Zeitschrift
- DDC Group:
- 610 Medizin
- Collection:
- Medizin
- Copyright:
- Rights reserved
- Accessibility:
- Free Access
- Title:
- Open medicine
- Publication:
-
Berlin: de Gruyter
- Note:
- Open Access
- Namensnennung 4.0 International
- Scope:
- Online-Ressource
- ISSN:
- 2391-5463
- ZDB-ID:
-
2829380-0
- VÖBB-Katalog:
- 35318930
- Keywords:
- Zeitschrift
- DDC Group:
- 610 Medizin
- Collection:
- Medizin
- Copyright:
- Rights reserved
- Accessibility:
- Free Access
Article
- Title:
- The role of auto-HSCT in extranodal natural killer/T cell lymphoma
- Publication:
-
Berlin: de Gruyter, 2024
- Language:
- English
- Information:
- Objectives: Autologous hematopoietic stem cell transplantation (auto-HSCT) is considered optional consolidation therapy especially for relapsed/refractory extranodal NK/T-cell lymphoma (ENKL), but its applications to newly diagnosed advanced-stage ENKL is currently limited. Methods: We collected 51 cases of newly diagnosed advanced-stage ENKL patients, including 26 with auto-HSCT and 25 with chemotherapy rather than HSCT, from our hospital between 2014/01 and 2023/12. We summarized the patients’ characteristics, conducted survival analysis of the 51 cases, and analyzed the potential benefits of auto-HSCT to ENKL patients. Results: It shows that after a median follow-up time of 39 months, the estimated 5-year overall survival (OS) of the 51 newly diagnosed advanced-stage ENKL patients is 73.4%, and their estimated 5-year progression-free survival (PFS) is 73.4%. For patients receiving auto-HSCT, the 5-year OS (91.7%) and PFS (91.0%) are significantly different from those of patients receiving chemotherapy without HSCT (OS 53.3%, PFS 54.5%) (p < 0.05). Univariate and multivariate analysis results suggest that only the l-asparaginase usage in chemotherapy showed significant impact on the OS, and none of concerned factors showed significant impact on the PFS. Conclusions: Auto-HSCT is indeed an option to newly diagnosed advanced-stage ENKL, but further studies are still required for more strict disease management.
- Scope:
- Online-Ressource
- Note:
- Open Access
- Archivierung/Langzeitarchivierung gewährleistet
- Keywords:
- extranodal NK/T-cell lymphoma ; chemotherapy ; autologous ; hematopoietic stem cell transplantation
- Copyright:
- CC BY
- Accessibility:
- Free Access
- Title:
- The role of auto-HSCT in extranodal natural killer/T cell lymphoma
- Publication:
-
Berlin: de Gruyter, 2024
- Language:
- English
- Information:
- Objectives: Autologous hematopoietic stem cell transplantation (auto-HSCT) is considered optional consolidation therapy especially for relapsed/refractory extranodal NK/T-cell lymphoma (ENKL), but its applications to newly diagnosed advanced-stage ENKL is currently limited. Methods: We collected 51 cases of newly diagnosed advanced-stage ENKL patients, including 26 with auto-HSCT and 25 with chemotherapy rather than HSCT, from our hospital between 2014/01 and 2023/12. We summarized the patients’ characteristics, conducted survival analysis of the 51 cases, and analyzed the potential benefits of auto-HSCT to ENKL patients. Results: It shows that after a median follow-up time of 39 months, the estimated 5-year overall survival (OS) of the 51 newly diagnosed advanced-stage ENKL patients is 73.4%, and their estimated 5-year progression-free survival (PFS) is 73.4%. For patients receiving auto-HSCT, the 5-year OS (91.7%) and PFS (91.0%) are significantly different from those of patients receiving chemotherapy without HSCT (OS 53.3%, PFS 54.5%) (p < 0.05). Univariate and multivariate analysis results suggest that only the l-asparaginase usage in chemotherapy showed significant impact on the OS, and none of concerned factors showed significant impact on the PFS. Conclusions: Auto-HSCT is indeed an option to newly diagnosed advanced-stage ENKL, but further studies are still required for more strict disease management.
- Scope:
- Online-Ressource
- Note:
- Open Access
- Archivierung/Langzeitarchivierung gewährleistet
- Keywords:
- extranodal NK/T-cell lymphoma ; chemotherapy ; autologous ; hematopoietic stem cell transplantation
- Copyright:
- CC BY
- Accessibility:
- Free Access
